iBET Welcomes Sanofi’s Microbial Platforms Leaders for Productive Discussions and Seminar
iNOVA4Health Seminar: Tuned Microbial Expression Systems for Highly Engineering Biologics
On April 4th, iBET had the pleasure of hosting representatives from Sanofi’s Microbial Platforms, for a morning of productive discussions and knowledge exchange.
iBET’s representatives, Professor Manuel Carrondo (iBET’s VP), Paula Alves (CEO of iBET), Patrícia Gomes-Alves (Head of the Sanofi Satellite Lab at iBET), and António Roldão (Coordinator of the Late-Stage R&D unit), welcomed Thomas Sauer (Head of the Microbial Platform, Global CMC Development), Daniel Degreif (Section Head of Microbial Strain Engineering, Microbial Platform) and Dominique Garnier (Global Head of Microbial Techno Platform, MSAT Vaccines).
From left to right: Manuel Carrondo, Daniel Degreif, Paula Alves, Thomas Sauer, Patrícia Gomes-Alves and Dominique Garnier
As part of their visit, Dr Sauer and Dr Degreif delivered a seminar on “Tuned Microbial Expression Systems for Highly Engineering Biologics” to the iNOVA4Health research unit community. The presentation highlighted the importance of microbial expression hosts, including bacteria and yeasts, as vital platforms for the industrial production of diverse biomolecules, particularly biopharmaceuticals.
Dr. Sauer currently leads the process development of next-generation microbially expressed biologics, such as nanobody and synthorin molecules. Dr. Degreif oversees microbial strain engineering within the platform, focusing on developing commercially viable strains.
Left to right: Professor Manuel Carrondo introduces the two seminar speakers, Dr Sauer and Dr Degreif. António Roldão provides a guided tour of some of iBET’s R&D facilities.
iBET extends its sincere thanks to Thomas, Daniel e Dominique for their visit and for delivering such an insightful seminar.
